With the relentless aging of the population worldwide, two major concerns need our immediate attention: the expected dramatic increase in disease and disability burden, and the decrease in the ratio of working individuals vs. retirees. A comprehensive approach involving experts… Continue Reading →

Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period. (1) Reed, C., Happich, M., Raskin, J. et al…. Continue Reading →